Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0519-0130 in Chronic Kidney Disease with Overweight or Obesity
NCT06717698Phase 2Recruiting
- Sponsor
- Novo Nordisk
- Start
- Dec 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 14
01
Overview
A Phase 2 trial of NNC0519-0130 in chronic kidney disease (CKD), sponsored by Novo Nordisk. Started Dec 2024; status: recruiting.
02
Drugs
NNC0519-0130
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06717698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06717698.